This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SOLEY, M. H. Articles by FOREMAN, N. Search for Related Content PubMed PubMed Citation Articles by SOLEY, M. H. Articles by FOREMAN, N.

GRAVES' DISEASE: TREATMENT WITH RADIOIODINE (I¹³¹)^*,

MAYO H. SOLEY, M.D., EARL R. MILLER, M.D. and NADINE FOREMAN, M.D.

Divisions of Medicine and Radiology of the University of California Medical School and the Thyroid Clinic of the University of California Hospital San Francisco, California

CARRIER-FREE I¹³¹ has been administered by us to patients with Graves' disease since August 1944 in order to study primarily: a) the efficiency of I¹³¹ as an agent employed to destroy hyperfunctioning thyroids subtotally; and b) the uptake of iodine by the thyroid before and after those symptoms of hyperfunction of the thyroid associated with Graves' disease have been relieved (1).

Up to the time of writing this summary, 68 patients with Graves' disease have been studied and sufficient data are available to permit reporting results in 46 patients. All these patients had undoubted Graves' disease varying in degree from mild to severe; the majority had moderately enlarged thyroids, moderate hyperthyroidism and (with one exception) no nodules in the thyroid. In the initial phases of this study, small (250 microcuries) doses of radioactive iodine were given at weekly intervals; more adequate single doses of 1000 to 4000 microcuries were given and repeated as necessary up to a total dose as high as 10,411 microcuries.

^* Read before the Annual Meeting of the American Association for the Study of Goiter, Toronto, Canada, May 6, 1948.

This article will be included in the bound volume of the "Transactions of the American Goiter Association," published by Charles C Thomas, Publisher, which will be available for sale early in 1949.

This study was supported by the Atomic Energy Commission and in part by an American Medical Association Therapeutic Research grant.

Present address: University of Iowa College of Medicine, Iowa City, la.

Grateful acknowledgment is made to Miss Jean Hitch for her assistance in coordinating this study and compiling data.

Received September 23, 1948.

This article has been cited by other articles:

				S. Silver, S. B. Yohalem, and R. A. Newburger PITFALLS IN DIAGNOSTIC USE OF RADIOACTIVE IODINE JAMA, September 3, 1955; 159(1): 1 - 5. [Abstract] [PDF]

				E. P. McCULLAGH and C. E. RICHARDS RADIOACTIVE IODINE IN THE TREATMENT OF HYPERTHYROIDISM Arch Intern Med, January 1, 1951; 87(1): 4 - 16. [Abstract] [PDF]

				D. E. CLARK, O. H. TRIPPEL, and G. E. SHELINE DIAGNOSTIC AND THERAPEUTIC USE OF RADIOACTIVE IODINE Arch Intern Med, January 1, 1951; 87(1): 17 - 24. [Abstract] [PDF]

				B. BEIDLEMAN TOXIC GOITER COMPLICATING DIABETES MELLITUS TREATED WITH RADIOACTIVE IODINE (I131) JAMA, November 11, 1950; 144(11): 925 - 927. [Abstract] [PDF]

				E. S. GORDON and E. C. ALBRIGHT TREATMENT OF THYROTOXICOSIS WITH RADIOACTIVE IODINE JAMA, July 29, 1950; 143(13): 1129 - 1132. [Abstract] [PDF]